Cadrenal Therapeutics Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing novel therapeutics for cardiovascular diseases, has announced new findings from a third-party research study conducted by Guidehouse. The study highlights the economic and medical burdens faced by patients with left ventricular assist devices (LVAD) who require chronic oral anticoagulation. It identifies tecarfarin, a Phase 3-ready oral anticoagulant under development by Cadrenal, as a potential alternative to warfarin. Tecarfarin is noted for its unique metabolic pathway, which may provide more consistent anticoagulation control and reduce the risk of drug interactions and adverse events. The research findings emphasize the significant clinical and economic impact of major bleeding events in this patient population, with hospitalization costs averaging $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds. The results have already been presented.